Mustang Bio, Inc. MBIO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Mustang Bio, Inc. (MBIO) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -407%.
About Mustang Bio
Mustang Bio is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3094% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$2M | -$16M | -$52M | -$78M | -$66M | -$60M | -$46M | -$31M | -$31M | -$13M |
| Free cash flow | — | -$11M | -$50M | -$68M | -$58M | -$39M | -$36M | -$26M | -$13M | — |
| EPS (diluted) | $-0.39 | $-38.57 | $-299.95 | $-504.65 | $-38.01 | $-57.02 | $-64.52 | $-57.02 | $-62.02 | $-57.52 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -20.2% | — | -1483.6% | -77.5% | -46.1% | -44.6% | -54.0% | -67.8% | -42.0% | -37.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Mustang Bio pay a dividend?
Not currently.
Is Mustang Bio a good stock to buy?
We do not give buy or sell advice. Mustang Bio scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.